Skip to main content

1 Result(s)

within Yosuke Hirasawa Remove this filter Hematology Remove this filter

and

  1. Article

    Open Access

    Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan

    Enfortumab vedotin (EV) is a novel antibody–drug conjugate approved for metastatic urothelial carcinoma (UC) refractory to prior treatment with immune checkpoint inhibitors (ICIs). However, the difference in e...

    Yosuke Hirasawa, Takahiro Adachi… in Journal of Cancer Research and Clinical On… (2024)

    Download PDF (688 KB) View Article